Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 221

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 221
---
 Equity

    Current liabilities:

    Accounts payable
    $
    6,579

    $
    3,237

    Accrued expenses
     
    7,439

    9,940

    Operating lease liabilities, current
     
    352

    852

    Total current liabilities
     
    14,370

    14,029

    Operating lease liabilities, noncurrent
     
    838

    12,434

    Total liabilities
     
    15,208

    26,463

    Commitments and contingencies (see Note 6)

    Stockholders’ equity:

    Preferred stock, $0.00001 par value, 5,000,000 shares authorized as of   December 31, 2024 and December 31, 2023.  No shares issued or   outstanding as of December 31, 2024 and December 31, 2023.
     
    —

    —

    Common stock, $0.00001 par value, 1,000,000,000 shares authorized as of December 31, 2024 and December 31, 2023;   51,935,134 and 51,445,862 shares issued and outstanding at   December 31, 2024 and December 31, 2023, respectively.
     
    —

    —

    Additional paid-in capital
     
    544,653

    535,468

    Accumulated deficit
     
    (368,712
    )

    (310,003
    )

    Accumulated other comprehensive income
     
    139

    224

    Total stockholders’ equity
     
    176,080

    225,689

    Total liabilities and stockholders’ equity
    $
    191,288

    $
    252,152

The accompanying notes are an integral part of these consolidated financial statements.

 104

PMV Pharmaceuticals, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

    Year Ended

    December 31,2024

    December 31,2023

    December 31,2022

    Operating expenses:

    Research and development
    $
    58,527

    $
    55,885

    $
    51,988